Intramuscular Toradol, gastrointestinal bleeding, and peptic ulcer perforation: a case report.
Peptic ulcers, perforations, and serious gastrointestinal bleeding have not been reported with intramuscular ketoralac tromethamine, the first parenteral nonsteroidal anti-inflammatory drug available for analgesic use. This article presents the case of a 39-year-old black female who underwent surgical repair of a perforated gastric ulcer after receiving multiple dosages of intramuscular ketoralac tromethamine in the emergency room over a period of 21/2 months for the treatment of pain due to chronic pancreatitis.
Yarboro
T L
TL
D000328:Adult; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007273:Injections, Intramuscular; D020911:Ketorolac Tromethamine; D010195:Pancreatitis / Q000188:drug therapy; D010439:Peptic Ulcer Perforation / Q000139:chemically induced*; D013276:Stomach Ulcer / Q000139:chemically induced*; D014046:Tolmetin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014325:Tromethamine / Q000008:administration & dosage / Q000009:adverse effects*
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D014325:Tromethamine; D020911:Ketorolac Tromethamine; D014046:Tolmetin